- Home
- TYRA vs PTLO Comparison
TYRA vs PTLO Comparison
Compare TYRA & PTLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- PTLO
- Stock Information
- Founded
- TYRA 2018
- PTLO 1963
- Country
- TYRA United States
- PTLO United States
- Employees
- TYRA N/A
- PTLO N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- PTLO Restaurants
- Sector
- TYRA Health Care
- PTLO Consumer Discretionary
- Exchange
- TYRA Nasdaq
- PTLO Nasdaq
- Market Cap
- TYRA 819.3M
- PTLO 821.9M
- IPO Year
- TYRA 2021
- PTLO 2021
- Fundamental
- Price
- TYRA $15.91
- PTLO $11.90
- Analyst Decision
- TYRA Strong Buy
- PTLO Buy
- Analyst Count
- TYRA 6
- PTLO 7
- Target Price
- TYRA $30.50
- PTLO $13.57
- AVG Volume (30 Days)
- TYRA 261.4K
- PTLO 1.8M
- Earning Date
- TYRA 03-18-2025
- PTLO 02-25-2025
- Dividend Yield
- TYRA N/A
- PTLO N/A
- EPS Growth
- TYRA N/A
- PTLO 56.82
- EPS
- TYRA N/A
- PTLO 0.42
- Revenue
- TYRA N/A
- PTLO $713,803,000.00
- Revenue This Year
- TYRA N/A
- PTLO $6.53
- Revenue Next Year
- TYRA N/A
- PTLO $11.42
- P/E Ratio
- TYRA N/A
- PTLO $28.18
- Revenue Growth
- TYRA N/A
- PTLO 11.02
- 52 Week Low
- TYRA $12.34
- PTLO $8.38
- 52 Week High
- TYRA $29.60
- PTLO $16.17
- Technical
- Relative Strength Index (RSI)
- TYRA 52.83
- PTLO 67.51
- Support Level
- TYRA $15.75
- PTLO $11.47
- Resistance Level
- TYRA $17.27
- PTLO $12.19
- Average True Range (ATR)
- TYRA 0.91
- PTLO 0.59
- MACD
- TYRA 0.20
- PTLO 0.36
- Stochastic Oscillator
- TYRA 65.99
- PTLO 91.69
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.